Skip to main content

Table 4 Treatment-related AEs in patients in two groups

From: Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma

AEs

TACE-apatinib, n (%)

TACE-alone, n (%)

P value

Grade 1

Grade 2

Grade 3

Grade 1

Grade 2

Grade 3

Leukocytes

2 (7.4)

2 (7.4)

0

4 (7.5)

0

0

0.133

Haemoglobin

0

2 (7.4)

1 (3.7)

0

2 (3.8)

0

0.272

Platelets

2 (7.4)

2 (7.4)

0

4 (7.5)

0

0

0.133

Bilirubin

3 (11.1)

4 (14.8)

0

11 (19.5)

3 (5.7)

0

0.264

ALT

3 (11.1)

5 (18.5)

0

12 (22.6)

7 (13.2)

0

0.402

AST

3 (11.1)

2 (7.4)

0

7 (13.2)

0

0

0.132

Fever

3 (11.1)

11 (40. 7)

0

7 (13.2)

18 (34.0)

0

0.833

Abdominal pain

4 (14.8)

3 (11.1)

0

9 (17.0)

5 (9.4)

1 (1.9)

0.891

Nausea/Vomiting

2 (7.4)

0

0

3 (5. 7)

0

0

1.000

Diarrhoea

2 (7.4)

5 (18.5)

0

2 (3.8)

0

0

0.004

Hypertension

0

6 (22.2)

13 (48.1)

0

0

0

0.000

Hand-foot syndrome

4 (14.8)

9 (33.3)

9 (33.3)

0

0

0

0.000

Oral ulcer

0

1 (3.7)

4 (14.8)

0

0

0

0.000

Proteinuria

2 (7.4)

3 (11.1)

3 (11.1)

0

0

0

0.000

  1. A P-value of < 0.05 is considered significant